Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
Clinical trials of novel therapeutics for Alzheimer’s Disease (AD) have consumed a significant amount of time and resources with largely negative results. Repurposing drugs already approved by the Food and Drug Administration (FDA), European Medicines Agency (EMA), or Worldwide for another indicatio...
Auteurs principaux: | Sergey Shityakov, Ekaterina V. Skorb, Carola Y. Förster, Thomas Dandekar |
---|---|
Format: | Article |
Langue: | English |
Publié: |
Frontiers Media S.A.
2021-10-01
|
Collection: | Frontiers in Chemistry |
Sujets: | |
Accès en ligne: | https://www.frontiersin.org/articles/10.3389/fchem.2021.736509/full |
Documents similaires
-
In silico repurposing of FDA-approved drugs as multi-target inhibitors of glioblastoma
par: Ridwan Abiodun Salaam, et autres
Publié: (2025-03-01) -
A Transcriptomics-Based Bioinformatics Approach for Identification and In Vitro Screening of FDA-Approved Drugs for Repurposing against Dengue Virus-2
par: Madhura Punekar, et autres
Publié: (2022-09-01) -
Editorial: Adopting drug repurposing to overcome drug resistance in cancer
par: Eswar Shankar, et autres
Publié: (2023-04-01) -
Network-based drug repurposing for potential stroke therapy
par: Qihui Wu, et autres
Publié: (2023-01-01) -
Approved drugs successfully repurposed against Leishmania based on machine learning predictions
par: Rafeh Oualha, et autres
Publié: (2024-09-01)